Townsquare Capital LLC Decreases Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Townsquare Capital LLC cut its position in Kenvue Inc. (NYSE:KVUE) by 45.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 28,796 shares of the company’s stock after selling 23,917 shares during the quarter. Townsquare Capital LLC’s holdings in Kenvue were worth $615,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Grove Bank & Trust grew its position in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in Kenvue in the fourth quarter valued at approximately $29,000. SRS Capital Advisors Inc. boosted its stake in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares in the last quarter. Fortitude Family Office LLC increased its position in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc increased its position in shares of Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after purchasing an additional 1,441 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Trading Up 3.0 %

Shares of KVUE stock opened at $23.42 on Friday. The company has a 50-day moving average of $22.91 and a two-hundred day moving average of $22.41. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The firm has a market cap of $44.93 billion, a PE ratio of 44.19, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.50%. The ex-dividend date is Wednesday, May 14th. Kenvue’s payout ratio is 154.72%.

Analyst Ratings Changes

Several research analysts recently weighed in on KVUE shares. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Canaccord Genuity Group upped their price objective on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Citigroup lifted their target price on shares of Kenvue from $21.00 to $22.00 and gave the stock a “neutral” rating in a research note on Monday, April 14th. Evercore ISI assumed coverage on shares of Kenvue in a research report on Monday, March 24th. They set an “in-line” rating and a $25.00 target price on the stock. Finally, Barclays decreased their price target on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, April 14th. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and an average target price of $24.42.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.